Weekly Paclitaxel and Carboplatin Concurrent with Radiotherapy for Lung Cancer

What Is Weekly Paclitaxel + Carboplatin Concurrent with Radiotherapy?

Weekly paclitaxel + carboplatin administered with radiotherapy is a concurrent chemoradiotherapy protocol used particularly for locally advanced (usually Stage III) non-small cell lung cancer (NSCLC).

Aim of Treatment

This treatment is generally used in Stage IIIA–IIIB non-small cell lung cancer (NSCLC). At these stages, the tumor:

• Is locally advanced,
• Has spread to lymph nodes, particularly mediastinal nodes,
• Has no distant metastases (M1),
• Cannot be surgically resected, or surgery is contraindicated.

The aim is to achieve local tumor control, reduce metastatic risk, and prolong survival.

How Does This Treatment Work?

1. Mechanism of Radiotherapy

• Radiotherapy targets cancer-cell DNA using high-energy X-rays.
• It is particularly effective during the G2/M phase of the cell cycle.
• It damages DNA, causing cells unable to repair the damage to undergo apoptosis (programmed cell death).
• The goal is to shrink the tumor mass and achieve local control.

2. Effects of Chemotherapy (Paclitaxel + Carboplatin)

Paclitaxel

• Acts as a microtubule stabilizer.
• Stops mitotic cell division, particularly in the M phase.
• Prevents uncontrolled tumor-cell proliferation.
• Also increases radiosensitivity, making cancer cells more susceptible to radiotherapy.

Carboplatin

• Is a platinum-derived DNA-damaging agent.
• Forms cross-links between DNA strands, inhibiting replication and transcription.
• Leads to cell death.
• Works synergistically with radiotherapy by making radiation-induced DNA damage more persistent.

3. Advantages of Concurrent Administration

• Radiosensitization: Chemotherapy enhances the effect of radiotherapy.
• Simultaneous cell killing: Two different mechanisms target cells at the same time.
• Combined control of local and microscopic spread: Radiotherapy acts locally while chemotherapy targets potential micrometastases.
• Early systemic intervention: Cells at risk of spreading are suppressed early.

Administration and Dose

• Radiotherapy continues daily except on weekends.
• Chemotherapy is given on one day each week.
• Carboplatin + paclitaxel is generally administered in day-treatment chemotherapy units, allowing patients to return home afterward. It may also be given in hospital if the patient is unwell.

Paclitaxel

• Dose: 45–50 mg/m²
• Administration: Intravenous infusion, generally over 1 hour
• Day: 1 day per week
• Purpose: Radiosensitization (enhancing radiotherapy effectiveness)

Carboplatin

• Dose: AUC 2 (calculated using the Calvert formula: Dose = AUC × [GFR + 25])
• Administration: Intravenous infusion, generally over 30–60 minutes
• Day: On the same day as paclitaxel, 1 time per week
• Treatment duration: Generally 6 weeks, for a total of 6 cycles

Radiotherapy

• Start: Begins in the same week as chemotherapy
• Dose/fraction: 1.8–2.0 Gy/fraction,
• 5 days/week (Monday–Friday)
• Total dose: 60–66 Gy delivered over 30–33 fractions
• Technology: Delivered using advanced planning techniques such as 3D-CRT, IMRT, or VMAT.

Adverse Reactions

These rates are average estimates based on clinical trials, particularly phase II/III studies, and treatment protocols. They may vary with patient characteristics.

• Fatigue 70–90%
• Alopecia (hair loss) 60–80%
• Leukopenia / neutropenia (low white blood cell count) 40–60%
• Mucositis / esophagitis (inflammation of the mouth and esophagus) 30–50%
• Anemia (low red blood cell count) 30–50%
• Nausea and vomiting 30–40%
• Thrombocytopenia (low platelet count) 20–30%
• Peripheral neuropathy (loss of sensation or tingling in the hands/feet) 20–30%
• Diarrhea 10–20%
• Radiation dermatitis (skin redness, peeling) 10–20%
• Elevated liver enzymes (AST/ALT) 10–15%
• Radiation pneumonitis 5–15%
• Kidney dysfunction (carboplatin) <5%
• Allergic reaction (during paclitaxel infusion) <5%

Points Requiring Attention

• Select patients appropriately: Patients should have a good performance status, and organ function should be assessed before treatment begins.
• Premedication must be given before chemotherapy: Dexamethasone and antihistamines should be administered beforehand to reduce paclitaxel-related allergic reactions.
• Monitor blood counts weekly: Neutropenia, thrombocytopenia, and anemia should be recognized early. Complete blood counts should be performed regularly to avoid treatment delays.
• Plan the radiotherapy field carefully: Modern techniques such as IMRT and VMAT should be used to protect the lungs, heart, and esophagus in particular from excessive doses.
• Take precautions against esophagitis during radiotherapy: Supportive care and an appropriate nutritional plan should address symptoms such as swallowing difficulties and mouth or throat pain.
• Monitor patients closely for pulmonary toxicity: Patients should be informed about symptoms of radiation pneumonitis, including cough and shortness of breath, and prompt action should be taken if they occur.
• Ask regularly about neurologic adverse reactions: Because paclitaxel can damage peripheral nerves, symptoms such as numbness or tingling in the hands and feet should be monitored.
• Administer infusions carefully: Ensure safe venous access to prevent extravasation, and have infusions administered by an experienced team.
• Monitor nutritional status and weight loss regularly: Adequate calorie and protein intake should be supported, particularly in patients with esophagitis.
• Aim to maintain treatment continuity: Radiotherapy sessions and chemotherapy cycles should be completed as scheduled where possible, with interruptions only when necessary.
• Monitor organ function (liver and kidneys): Check liver and kidney function with biochemical tests before every cycle.
• Teach patients and families about possible emergencies: Clearly explain that symptoms such as fever, shortness of breath, or inability to swallow require prompt medical attention.